Marshall Wace, LLP Fibrogen Inc Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Fibrogen Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 1,444,842 shares of FGEN stock, worth $476,797. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,444,842

Holding current value

$476,797

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.33 - $1.26 $476,797 - $1.82 Million	1,444,842 New	1,444,842 $577,000
Q4 2022 Feb 14, 2023	SELL	$13.27 - $17.73 $85,472 - $114,198	-6,441 Reduced 0.85%	753,546 $12.1 Million
Q3 2022 Nov 14, 2022	BUY	$11.4 - $14.6 $8.66 Million - $11.1 Million	759,987 New	759,987 $9.89 Million
Q2 2021 Aug 13, 2021	BUY	$18.57 - $35.68 $8.56 Million - $16.4 Million	460,842 New	460,842 $12.3 Million
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $2.71 Million - $3.76 Million	-78,326 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$36.98 - $48.45 $2.9 Million - $3.79 Million	78,326 New	78,326 $2.9 Million
Q1 2019 May 14, 2019	SELL	$42.83 - $59.91 $5.31 Million - $7.43 Million	-123,947 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $4.71 Million - $7.46 Million	123,947 New	123,947 $5.74 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

Primecap Management CO Pasadena, CA

9.91M
Shares

$3.27 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

6.8M
Shares

$2.24 Million
0.05% of portfolio
Vanguard Group Inc Valley Forge, PA

5.88M
Shares

$1.94 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

3.91M
Shares

$1.29 Million
0.0% of portfolio
Black Rock Inc. New York, NY

2.41M
Shares

$795,184
0.0% of portfolio

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $30.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account